Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 53

1.

A review of therapeutic uses of mirtazapine in psychiatric and medical conditions.

Alam A, Voronovich Z, Carley JA.

Prim Care Companion CNS Disord. 2013;15(5). pii: PCC.13r01525. doi: 10.4088/PCC.13r01525. Epub 2013 Oct 10.

2.

Role of mirtazapine in the treatment of antipsychotic-induced akathisia.

Hieber R, Dellenbaugh T, Nelson LA.

Ann Pharmacother. 2008 Jun;42(6):841-6. doi: 10.1345/aph.1K672. Epub 2008 May 6.

PMID:
18460588
3.

Mirtazapine for treatment of depression and comorbidities in Alzheimer disease.

Raji MA, Brady SR.

Ann Pharmacother. 2001 Sep;35(9):1024-7.

PMID:
11573849
5.

A review of antidepressant therapy in primary care: current practices and future directions.

Kennedy SH.

Prim Care Companion CNS Disord. 2013;15(2). pii: PCC.12r01420. doi: 10.4088/PCC.12r01420. Epub 2013 Apr 11.

6.

Mirtazapine: only for depression?

San L, Arranz B.

Acta Neuropsychiatr. 2006 Jun;18(3-4):130-43. doi: 10.1111/j.1601-5215.2006.00143.x.

PMID:
26989965
7.

Safety of mirtazapine: a review.

Montgomery SA.

Int Clin Psychopharmacol. 1995 Dec;10 Suppl 4:37-45. Review. Erratum in: Int Clin Psychopharmacol 1996 Jun;11(2):153.

PMID:
8930008
8.

Cognitive Behavioral Therapy for Insomnia Comorbid With Psychiatric and Medical Conditions: A Meta-analysis.

Wu JQ, Appleman ER, Salazar RD, Ong JC.

JAMA Intern Med. 2015 Sep;175(9):1461-72. doi: 10.1001/jamainternmed.2015.3006.

PMID:
26147487
9.

A meta-analysis of clinical trials comparing mirtazapine with selective serotonin reuptake inhibitors for the treatment of major depressive disorder.

Papakostas GI, Homberger CH, Fava M.

J Psychopharmacol. 2008 Nov;22(8):843-8. doi: 10.1177/0269881107083808. Epub 2008 Feb 28.

PMID:
18308801
10.

Psychiatric Co-morbidity and Efficacy of Mirtazapine Treatment in Young Subjects With Chronic or Cyclic Vomiting Syndromes: A Case Series.

Coskun M, Alyanak B.

J Neurogastroenterol Motil. 2011 Jul;17(3):305-11. doi: 10.5056/jnm.2011.17.3.305. Epub 2011 Jul 14.

11.

Mirtazapine for the Treatment of Chronic Pruritus.

Khanna R, Boozalis E, Belzberg M, Zampella JG, Kwatra SG.

Medicines (Basel). 2019 Jul 6;6(3). pii: E73. doi: 10.3390/medicines6030073.

12.

Mirtazapine: a newer antidepressant.

Hartmann PM.

Am Fam Physician. 1999 Jan 1;59(1):159-61. Review.

13.

Antidepressant-induced sexual dysfunction.

Gregorian RS, Golden KA, Bahce A, Goodman C, Kwong WJ, Khan ZM.

Ann Pharmacother. 2002 Oct;36(10):1577-89. Review.

PMID:
12243609
14.

Mirtazapine in Comorbid Major Depression and Alcohol Dependence: An Open-Label Trial.

Cornelius JR, Douaihy AB, Clark DB, Chung T, Wood DS, Daley D.

J Dual Diagn. 2012 Sep 1;8(3):200-204. Epub 2012 Aug 8.

15.

Study of the use of antidepressants for depression in dementia: the HTA-SADD trial--a multicentre, randomised, double-blind, placebo-controlled trial of the clinical effectiveness and cost-effectiveness of sertraline and mirtazapine.

Banerjee S, Hellier J, Romeo R, Dewey M, Knapp M, Ballard C, Baldwin R, Bentham P, Fox C, Holmes C, Katona C, Lawton C, Lindesay J, Livingston G, McCrae N, Moniz-Cook E, Murray J, Nurock S, Orrell M, O'Brien J, Poppe M, Thomas A, Walwyn R, Wilson K, Burns A.

Health Technol Assess. 2013 Feb;17(7):1-166. doi: 10.3310/hta17070.

16.
17.

Understanding the clinical profile of a drug on the basis of its pharmacology: mirtazapine as an example.

Howland RH.

J Psychosoc Nurs Ment Health Serv. 2008 Dec;46(12):19-23. Review.

PMID:
19133491
18.

Defining the role of mirtazapine in the treatment of refractory pruritus.

Fawaz B, Chamseddin BH, Griffin JR.

J Dermatolog Treat. 2019 Jun 27:1-5. doi: 10.1080/09546634.2019.1630702. [Epub ahead of print]

PMID:
31180795
19.

Case series of perimenopausal women with insomnia treated with mirtazapine followed by prolonged-release melatonin add-on and monotherapy.

Dolev Z.

Arch Womens Ment Health. 2011 Jun;14(3):269-73. doi: 10.1007/s00737-011-0205-7. Epub 2011 Feb 12.

PMID:
21311927
20.

Mirtazapine, and mirtazapine-like compounds as possible pharmacotherapy for substance abuse disorders: evidence from the bench and the bedside.

Graves SM, Rafeyan R, Watts J, Napier TC.

Pharmacol Ther. 2012 Dec;136(3):343-53. doi: 10.1016/j.pharmthera.2012.08.013. Epub 2012 Aug 29. Review.

Supplemental Content

Support Center